Point72 Asset Management’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-106,151
Closed -$165K 4232
2025
Q4
$165K Sell
106,151
-271,888
-72% -$434K ﹤0.01% 3676
2025
Q3
$597K Buy
+378,039
New +$657K ﹤0.01% 1866
2023
Q4
Sell
-33,200
Closed -$104K 2581
2023
Q3
$104K Sell
33,200
-67,800
-67% -$273K ﹤0.01% 1959
2023
Q2
$464K Buy
101,000
+66,800
+195% +$307K ﹤0.01% 1278
2023
Q1
$169K Sell
34,200
-386,857
-92% -$1.9M ﹤0.01% 1531
2022
Q4
$2.3M Buy
421,057
+386,157
+1,106% +$2.37M 0.01% 916
2022
Q3
$227K Buy
+34,900
New +$195K ﹤0.01% 1257

Other funds holding MXCT

Point72 Asset Management's MXCT Position: Q1 2026 in Review

Point72 Asset Management sold out of MaxCyte (MXCT) in Q1 2026, closing a stake of 106,151 shares — an estimated $165K sold.

Point72 Asset Management first reported a position in MXCT in Q3 2022 and held it in 7 quarters. The position peaked at $2.3M in Q4 2022. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Point72 Asset Management reported no remaining MaxCyte position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 106,151 MaxCyte shares in Q1 2026, an estimated $165K.
  • Point72 Asset Management first reported a position in MaxCyte in Q3 2022 and held it in 7 quarters.
  • Point72 Asset Management's MaxCyte position peaked at $2.3M in Q4 2022.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.